KRAS and non-small cell lung carcinoma: In particular, Nygaard et al. [16], using amplification refractory mutation system-quantitative PCR (ARMS-qPCR) to detect seven KRAS mutations in plasma samples from advanced NSCLC, showed the independent negative prognostic value of plasma KRAS mutations for OS, but not for PFS.